[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"staphylococcal-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:staphylococcal-infections":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,54,86,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054082","modeling-host-pathogen-interaction-using-lymphoid-organoids-100054082",false,"NCT06479837","Modeling Host-Pathogen Interaction Using Lymphoid Organoids","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged \\>=2 yrs.\n* Undergoing tonsillectomy as part of their clinical care.\n* Able to provide informed consent (for ages \\>=18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 yrs).\n* Willing to allow samples and data to be stored and shared for future secondary research.\n* Willing to allow future genetic testing on their biospecimens.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Active infection.\n* Active tonsilitis.\n* Pregnant.\n* Diagnosed with an immunosuppressive condition or currently taking immunosuppressive medications.\n* Current or past intravenous drug use.\n* Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study","ALL","2 Years","120 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","Background:\n\nStaphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these infections can lead to paralysis and death. Researchers do not know how S. aureus interacts with a person s cells to cause infections in the spine.\n\nObjective:\n\nTo learn how S. aureus interacts with cells in the body using tissues from tonsils discarded after standard surgery to remove them.\n\nEligibility:\n\nPeople aged 2 years and older who are scheduled to have their tonsils removed.\n\nDesign:\n\nResearchers will select participants for the study based on review of their existing medical records, including results of blood tests; any imaging scans, including x-rays; and reports about tissue specimens.\n\nParticipants will answer questionnaires about their health and past infections. They can do this online or on paper.\n\nParticipants will collect a nasal swab 1 week before their surgery. They will be given a tool that looks like a long cotton swab. They will twirl it around inside their nose. The swab will pick up cells and fluids that will be used for research.\n\nAfter their surgery, the participant s surgeon will save samples of tonsil tissue. The surgeon will send these tissue samples and the nasal swab to researchers at the NIH.\n\nThese tissues and the swab will be used in studies to help researchers understand how S. aureus interacts with cells in the body. They hope these studies will help them find better ways to treat S. aureus infections.",[24],"Staphylococcal Infections",[26,27,28],"Organoid","Staphylococcus","Host-pathogen Interactions","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-07-16",{"date":37,"type":20},"2044-12-01",{"name":39,"class":40},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",2,{"id":43,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":45,"keywords":46,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":53,"locationsCount":41},"100552957",{"count":19,"type":20},[24],[26,27,28],"2026-07-01",{"date":49,"type":33},"2026-07-02",{"date":51,"type":20},"2026-07-07",{"date":37,"type":20},{"name":39,"class":40},{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100260079","phase-1-standard-treatment-associated-with-phage-therapy-versus-placebo-for-diabetic-foot-ulcers-infected-by-s-aureus-100260079","NCT02664740","Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus","Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial","PhagoPied","Participant pre-inclusion criteria:\n\n* The patient must have given his\u002Fher informed and signed consent\n* The patient must be insured or beneficiary of a health insurance plan\n* The patient is at least 18 years old\n* The patient has type 1 or type 2 diabetes\n* The patient is hospitalized\u002Fconsulting in a participating centre\n* The patient has a wound below the ankle that has be evolving for \\>2 weeks\n* The patient has a neuropathic foot wound, classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,\n\n  * without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure \\> 50 mm Hg or toe systolic arterial pressure \\> 30 mm Hg or TcpO2 \\> 30 mm Hg )\n  * with a surface area ≥ 0,5 cm2\n  * With IWGDF\u002FIDSA grade 2 or 3 infection without osteomyelitis (normal radiography\\*)\n* Females of childbearing potential or Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration\n* Negative pregnancy test must be obtained before starting any experimental drug\n* Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months)\n\nParticipant final inclusion criteria:\n\n* The patient has a neuropathic foot wound:\n\n  * Classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,\n* without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure \\> 50 mm Hg or toe systolic arterial pressure \\> 30 mm Hg or TcpO2 \\> 30 mm Hg )\n* with a surface area ≥ 0,5 cm2\n\n  * With IWGDF\u002FIDSA grade 2 or 3 infection without osteomyelitis\n* The patient's wound is monoinfected by methicillin-resistant or susceptible S. aureus (MSSA or MRSA ), or infected by MSSA or MRSA and other bacteria (a total of 3 bacteria when accounting for MSSA or MRSA)\n* The Phagogram of the patient demonstrated that the strains are susceptible to at least one phage(PP1493 and\u002For PP1815).\n\nParticipant pre-exclusion criteria:\n\n* The patient is participating in, or has participated in over the past three months, another trial\n* The patient is participating in, or has participated in over the past three months, another study that may interfere with the results or conclusions of this study\n* The patient is in an exclusion period determined by a previous study\n* The patient is under judicial protection, or is an adult under guardianship\n* It is impossible to correctly inform the patient\n* The patient refuses to sign the consent\n* The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug\n* Women\u002FMen refusing to use an effective contraception during and1 month after the last administration of study drug\n\nParticipant final exclusion criteria:\n\n* The patient refuses to participate to the study\n* The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug\n* Women\u002FMen refusing to use an effective contraception during and1 month after the last administration of study drug\n* Patients with diabetic foot wounds associated with clinical or radiographic signs of arthritis or osteomyelitis\\*\n* Patient is not infected by S. aureus or infected by more than 3 bacteria even if the culture isolates a S. aureus.","18 Years",{"count":64,"type":20},60,"INTERVENTIONAL",[67,68],"PHASE1","PHASE2","The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.",[71,24],"Diabetic Foot",[73],"Phage Therapy","NOT_YET_RECRUITING","2026-03-18",{"date":77,"type":33},"2026-03-20",{"date":79,"type":20},"2026-09-01",{"date":81,"type":20},"2028-11",{"name":83,"class":84},"Centre Hospitalier Universitaire de Nīmes","OTHER",6,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":65,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100581290","phase-4-unbound-cloxacillin-concentrations-during-continuous-infusion-100581290","NCT06848387","Unbound Cloxacillin Concentrations During Continuous Infusion","Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump","KLONC","Inclusion Criteria:\n\n* Age 18 years or older\n* Treating physician has decided to start continuous infusion of cloxacillin\n\nExclusion Criteria:\n\n* Unwilling or unable to provide written informed consent",{"count":95,"type":20},25,[97],"PHASE4","Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK\u002FPD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.",[24],[101],"cloxacillin","2026-02-12",{"date":104,"type":33},"2026-02-17",{"date":106,"type":33},"2026-01-14",{"date":108,"type":20},"2027-12",{"name":110,"class":84},"Emeli Månsson",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":65,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":111},"100508340","phase-4-adjunctive-clindamycin-for-the-treatment-of-skin-and-soft-tissue-infections-a-randomized-controlled-trial-100508340","NCT05899140","Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial","Adjunctive Clindamycin Versus Standard of Care for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled, Open-label Superiority Phase 4 Trial","SoTiClin","Inclusion Criteria:\n\n1. Adults (age ≥18 years);\n2. Need for a treatment (incision\u002Fdrainage ± antibiotic treatment po or iv) of an SSTI;\n3. S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen);\n4. Onset of symptoms within the last 4 weeks;\n5. Randomisation possible within 72 hours from collection of the initial culture\n6. Ability to conduct the follow-up visits either during admission or at home\n7. Initial culture collected within 48 hours of hospital admission\n8. Willingness to participate in the study.\n\nExclusion Criteria\n\n1. Previous allergic reaction to clindamycin\n2. Previous antibiotic-associated diarrhea\n3. Previous study participation\n4. Pregnancy as confirmed by a beta-HCG rapid test.\n5. Started treatment with clindamycin prior to clinic presentation;\n6. Documented systemic antibiotic treatment within the previous 14 days\n7. Co-administration of other protein synthesis inhibitors (e.g. macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol);\n8. Co-administration of toxin inducers (trimethoprim-sulfamethoxazole)\n9. Severe illness (patient expected to die in the following 24 hrs);\n10. Chronically infected wounds (\\>4 weeks of symptoms);\n11. Infections associated with any of the following (due to mixed infection): a) Human or animal bites;b) Prosthetic or implantable devices; c) Decubitus ulcers; d) Diabetic foot ulcers, infected ulcers secondary to peripheral artery disease, chronic venous insufficiency; e) Suspected Buruli ulcer; f) Infected burns.\n12. Hospital-acquired infection including post-surgical site infections",{"count":121,"type":20},100,[97],"This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.",[125,24,126],"Skin Infection","Staphylococcus Aureus Infection",[128,129,130],"SSTI","Staphylococcus aureus","Panton-Valentine leukocidin","2024-12-04",{"date":133,"type":33},"2024-12-09",{"date":135,"type":33},"2024-03-15",{"date":137,"type":20},"2026-07-31",{"name":139,"class":84},"Frieder Schaumburg"]